An article recently published in Molecular Brain explores Ghrelin deficits within Parkinson’s disease. By using disease-specific induced pluripotent stem cells (iPSCs) containing the PARK2 gene mutations, the researchers reveal that a receptor for Ghrelin might be a potential new therapeutic target for the disease.